Key statistics
On Tuesday, BioMarin Pharmaceutical Inc (BM8:HAN) closed at 50.80, 16.01% above the 52 week low of 43.79 set on Dec 16, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 49.95 |
|---|---|
| High | 50.80 |
| Low | 49.95 |
| Bid | 50.50 |
| Offer | 50.72 |
| Previous close | 50.08 |
| Average volume | 0.00 |
|---|---|
| Shares outstanding | 192.11m |
| Free float | 190.68m |
| P/E (TTM) | 22.44 |
| Market cap | 11.50bn USD |
| EPS (TTM) | 2.67 USD |
Data delayed at least 15 minutes, as of Feb 17 2026 16:25 GMT.
More ▼
Press releases
- BioMarin to Host Fourth Quarter and Full-Year 2025 Financial Results Conference Call and Webcast on Monday, February 23, 2026, at 4:30pm ET
- BioMarin Announces Closing of Private Offering of Senior Notes
- BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility
- BioMarin Announces Proposed Private Offering of Senior Notes and Syndication of New Senior Secured Term Loan Facility
- BioMarin Appoints Arpit Davé Chief Digital and Information Officer
- BioMarin to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, at 11:15 am PT / 2:15 pm ET, in San Francisco, CA
- Veeva and BioMarin Form Long-Term Strategic Partnership
- Veeva and BioMarin Form Long-Term Strategic Partnership
- BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
More ▼
